Results 231 to 240 of about 191,225 (267)

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

Molecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim, Aurelie Genoux, Nadiia Zubchuk, Haoyang Zheng, Perla Salameh, Theo Ziegelmeyer, Fabien Dalonneau, Margot Rouchette, Christiane Oddou, Simona Miron, Helene Polveche, Adiilah Mamode Cassim, Carmen Garrido, Eleni Nikolakaki, Didier Auboeuf, Tao Jia, Sophie Zinn‐Justin, Beatrice Eymin   +17 more
wiley   +1 more source

The Influence of Servant Leadership on the Professional Well-Being of Kindergarten Teachers: A Moderated Mediation Model. [PDF]

Behav Sci (Basel)
Yu D, Yue W, Hao S, Li D, Wu Q.
europepmc   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

Enhanced school-based vision screening in Kumasi, Ghana: a pilot study to assess feasibility. [PDF]

Front Med (Lausanne)
Asare AO, Ansah-Asiedu E, Ablordeppey P, Doku ET, Agbeshie GK, Gle SA, Mensah NAO, Yeboah CN, Adikah RE, Baidoo DA, Darko CK, Arkhurst EE, Watt MH, Vegunta S, Acquah EA, Afake H, Agyekum S, Akuffo KO.   +17 more
europepmc   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source

The distribution of power and inclusiveness across deep time. [PDF]

Sci Adv
Feinman GM, Stasavage D, Carballo DM, Barber SB, Green A, Holland-Lulewicz J, Lawrence D, Munson J, Nicholas LM, Fulminante F, Klassen S, Kintigh KW, Douglass J.   +12 more
europepmc   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

Molecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir, Elena Haro‐Martínez, Sandra Blasco‐Benito, Chiara Cannatà, José Ángel Palomeque, Anna López‐Plana, Maria Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià‐Terrassa   +9 more
wiley   +1 more source

Psychological Safety of School Administrators: A Dual Reality. [PDF]

J Sch Leadersh
Wang F.
europepmc   +1 more source

A scoping review of instruments measuring the implementation of the Health-Promoting School approach. [PDF]

Health Promot Int
Delbosq S, Bessems K, Branda M, Dadaczynski K, Vennegoor G, Leksy K, Klomstén AT, Velasco V.   +7 more
europepmc   +1 more source